{'fraction_non_alphanumeric': 0.04212299915754002, 'fraction_numerical': 0.015164279696714406, 'mean_word_length': 4.91044776119403, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 1, 'zh_pornsignals.json': 0}}
Treatment of Vaginal Intraepithelial Neoplasia (Primarily Low Grade) with Imiquimod 5% Cream

Objective. Treatment of human papillomavirus (HPV)-associated vaginal lesions (vaginal intraepithelial neoplasia [VAIN]) can be expensive, tedious, and morbidity inducing. Imiquimod 5% cream, a safe and effective treatment of external genital warts, enhances the immune response to HPV infection. Materials and Methods. Imiquimod 5% cream was used to treat 56 young women with VAIN. One sachet of cream (0.25 g) was placed in the vagina with an applicator once weekly for 3 weeks (except for the first four patients, who were treated twice weekly). Results. Thirty-six of the 42 patients (86%) available for follow-up were clear of VAIN lesions (as assessed by colposcopy) 1 week or later after the last dose of treatment. The remaining six patients cleared after a total of two (five patients) and three (one patient) treatment cycles. Vulvar or vestibular excoriation was reported in only 2 of 56 patients. No patients had vaginal ulceration. Conclusions. A very low dosing regimen of imiquimod 5% cream appears to be an effective and well-tolerated treatment for VAIN (primarily low grade.)